SRZN - Surrozen, Inc./DE
28.14
-2.495 -8.866%
Share volume: 111,009
Last Updated: 04-24-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.22%
PREVIOUS CLOSE
CHG
CHG%
$30.64
-2.50
-0.08%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-08-2024 | 08-12-2024 | 11-06-2024 | 05-09-2025 | 11-07-2025 | 03-23-2026 | |
| Total revenue | 0.000 | 0.000 | 10.000 M | 983.000 K | 983.000 K | 528.000 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 10.000 M | 983.000 K | 983.000 K | 528.000 K | |
| nan% | inf% | -90.17% | 0.00% | -46.29% | |||
| Operating expenses | 9.130 M | 9.049 M | 8.768 M | 10.534 M | 11.868 M | 13.167 M | |
| Selling general and admin | 3.883 M | 3.714 M | 3.568 M | 3.976 M | 4.094 M | 4.176 M | |
| Research and development | 5.247 M | 5.335 M | 5.200 M | 6.558 M | 7.774 M | 8.991 M | |
| Total expenses | 9.130 M | 9.049 M | 8.768 M | 10.534 M | 11.868 M | 13.167 M | |
| -0.89% | -3.11% | 20.14% | 12.66% | 10.95% | |||
| Operating income | -9.130 M | -9.049 M | 1.232 M | -9.551 M | -10.885 M | -12.639 M | |
| Ebit | -9.215 M | -25.751 M | -1.865 M | -44.723 M | -72.554 M | -31.485 M | |
| Pretax income | -8.830 M | -25.261 M | -1.434 M | -44.427 M | -71.643 M | -30.697 M | |
| 186.08% | -94.32% | 2,998.12% | 61.26% | -57.15% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -8.830 M | -25.261 M | -1.434 M | -26.970 M | -71.643 M | -183.159 M | |
| -186.08% | 94.32% | -1,780.75% | -165.64% | -155.66% |